WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Wednesday, July 18, 2018

Compound identified that protects against neurodegeneration

July 18, 2018








Researchers from the University of Liverpool have identified a new compound that protects against neurodegeneration in nematode worms. The discovery may enable novel treatments for human neurodegenerative diseases to be developed in the future.

With the predicted growth of the global ageing population, cases of age-associated  such as Alzheimer's disease, Parkinson's disease and  (ALS) are expected to rise. However, most current therapies do not decelerate or modify , and efforts to develop new treatments have been met with high attrition rates.

The antiepileptic drug ethosuximide has recently been shown to protect against neurodegeneration in various nematode worm and rodent models. It is therefore a promising repurposing candidate for the treatment of multiple neurodegenerative diseases. However, high concentrations of the drug are required for its protective effects in animal models, which may limit its translational potential and impede the identification of its molecular mechanism of action.

100 times more potent

Researchers, led by Professor Alan Morgan from the University's Institute of Translational Medicine, aimed to develop a more potent version of the drug to avoid these impediments.

In a collaborative approach involving University of Liverpool experts in Chemistry, (Professor Paul O'Neill, Dr. Neil Berry), Nuclear magnetic resonance (Dr. Marie Phelan) and  (Dr. Shi Quan Wong, Professor Bob Burgoyne, Dr. Jeff Barclay) the team identified a novel neuroprotective molecule called MPS that is chemically similar to ethosuximide, but is much more potent in reducing neurodegeneration in a worm model of ALS.

Professor Morgan, said: "Our research has revealed a novel neuroprotective activity of MPS that is over 100 times more potent than ethosuximide. This discovery may have translational potential for the  of ALS and potentially other neurodegenerative diseases."

More information: Shi Quan Wong et al, α-Methyl-α-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-43 proteinopathy, Neurobiology of Disease (2018).  DOI: 10.1016/j.nbd.2018.06.013

Journal reference: Neurobiology of Disease


https://medicalxpress.com/news/2018-07-compound-neurodegeneration.html

No comments:

Post a Comment